nobel ultimately rejected akzo off by more than 2% this morning. >>> and stmicro will replace nokia in the cac 40. the move will become effective on the 18th of september a bit of buying in the run up to that change. we're seeing shares up by 0.9% >>> and volkswagen is seeking to sell non-core assets comprising as much as 20% of the group's revenue. speaking to the "wall street journal," the chief executive said a dedicated team was working to shed assets no longer deemed critical. he also commented on media reports that volkswagen is considering a tie up with fiat chrysler calling it speculation. >>> e-mail the show. the address is streetsignseurope@cnbc.com i love seeing your tweets. you can also follow us on twitter, streetsignseurope@cnbc and tweet me at @carolincnbc. >>> we will go for a quick break, coming up on the show, an explosive situation with no solution in sight. we'll bring you the latest on north korea as the region braces for another potential missile launch who knew that phones would start doing everything? entertaining us, getting us back on track, and finding us

july, akzo's ceo also quit due to health reasons. >>> second quarter results for c cloudera rose. it is raising its full-year outlook. up 44% this morning. >>> shares of american outdoor brands are sliding the gunmaker reported first quarter earnings and revenue that fell short of forecast. this quarter faced a challenging comparison to last year which was driven by demand for firearms on concerns about potential gun control legislation in the u.s >>> finisar is reporting first quarter earnings in line with estimates. the fiberoptics company gave a second quarter outlook that missed forecasts. >>> veriphone reporting a surprised third quarter loss due to restructuring charges related to china operations. they also gave a weak outlook for the current quarter redfin's second quarter earnings in line with expectations. the. >>> zumiez is reporting a narrower second quarter loss revenue slightly topping forecasts. same-store sales rose nearly 5%. >>> merck says a closely watched clinical trial shows combining a drug with chemotherapy appears to provide durable benefits for people with